Technology Licensing Gap Widens 11-Fold in Five Years
Funding Shortages Force Biotech Ventures to License Out Early
Need to Invest in Late-Stage Development and Strengthen Cooperation with China

Editor's NoteAs China's industrial rise rapidly expands into new areas, its growing influence in the biotech sector is becoming increasingly pronounced. In particular, in technology deals involving drug candidates with global Big Pharma companies, China has continued to achieve unprecedented or highly exceptional results in recent years, easily overtaking competitors, including Korea. This series examines the source of China's strength and how Korea, once a leader in the field thanks to its advantage in trust built across the global industry, should respond going forward.

1. Big Pharma Scoops Up Chinese Drug Candidates Wholesale

2. Hard to Sell Even Once, but China Sells Again and Again

3. Chinese Drug Sold for $8.4 Billion: Results Three Years Later

4. Can Korea Endure the Grueling Late-Stage Development Race?


In 2021, the value of innovative drug licensing deals from Korea and China stood at $11 billion (approximately KRW 14.718 trillion) and $13.4 billion (approximately KRW 17.9292 trillion), respectively. But in the first half of this year, China recorded approximately $99.7 billion (approximately KRW 133.3986 trillion) in licensing deals, while Korea managed just $8.7 billion (approximately KRW 11.6406 trillion). The two countries were on a similar footing just five years ago, but China has now widened the gap to about 11 times Korea's level and is pulling further ahead. China's biotech rise, which began with competition in drug-candidate discovery, is spreading to clinical development and global licensing deals, rapidly widening the gap between the two countries' industries.


[China Shock, K-Industry on the Brink | Biotech] 4. Can Korea Endure the Grueling Late-Stage Development Race? View original image

According to the National Development Institute of Korean Medicine, 1,337 domestic drug candidates entered preclinical or clinical development between 2022 and 2024, ranking Korea third globally behind the United States and China. However, the pipeline thins sharply as candidates advance through clinical development. Just 57 domestic drug candidates have currently reached Phase 3 trials. There are 851 candidates in the discovery stage and 760 in preclinical development, meaning 74.5% have yet to enter clinical trials. Industry officials say the gap is widening not in the ability to discover candidates, but in the ability to turn them into clinical data and advance them to late-stage development.


Lee Seung-kyou, vice chairman of the Korea Biotechnology Industry Organization (KoreaBIO), said, "Chinese companies often negotiate licensing deals after securing clinical data, whereas domestic companies often pursue deals based on preclinical data. Clinical trials require funding, but investment in this stage is not sufficient in Korea."


Of the 1,929 pipeline candidates held by Korea's domestic industry, 1,505, or 78.0%, belong to biotech ventures. Mid-sized companies hold 399, while large companies hold 25. In China, large pharmaceutical companies such as Hengrui Pharmaceuticals develop more than 100 innovative drug candidates in clinical trials at the same time, accepting the failure of some assets while continuing to develop the next candidates. In Korea, by contrast, biotech ventures hold most of the pipeline, and their future investment and even survival may depend on the success or failure of just one or two key candidates.


An executive at a biotech venture with experience licensing a drug candidate to a Big Pharma company said, "We have a candidate currently in Phase 2 trials and are confident it will succeed, but we are planning to license it to a Big Pharma company relatively early, sometime next year." The executive added, "The reason we want to sign a deal before the trial is complete is entirely the cost. We know it would be advantageous to continue the trial as long as possible and license the candidate at a later stage, but realistically, we cannot afford the costs all the way through."

[China Shock, K-Industry on the Brink | Biotech] 4. Can Korea Endure the Grueling Late-Stage Development Race? View original image

Domestic biotech investment totaled KRW 1.9306 trillion from the beginning of this year through September 22, exceeding last year's full-year total. What the industry sees as a problem is not the total amount, but how the money is flowing. Funding is pouring into companies with proven clinical results or track records of technology transfers, while biotech ventures that need to move beyond drug-candidate discovery and through early- and mid-stage clinical trials continue to report funding shortages. Costs typically rise to tens or even hundreds of billions of won as candidates advance through clinical trials, but there is little long-term capital available to support them over several years.


Some also point out that investment statistics may obscure what is happening on the ground. Lee said, "The size of investment funds may appear to have grown from last year, but a closer look shows that large amounts of money are often being absorbed by companies that are already doing well. Almost no investment is going to startups or companies that could continuously supply new pipelines." He therefore recommended leaving areas where private investors can invest to the private sector, while using policy funding to fill gaps in areas that private investors may hesitate to enter because of the risks, thereby sustaining the ecosystem.


This recommendation leads to the argument that the nature of funding needs to change rather than simply increasing total biotech investment. In addition to broadly distributing funding for drug-candidate discovery and early clinical trials, Korea needs growth capital to select assets whose competitiveness has been demonstrated through clinical data and push them through late-stage development. Since policy funding cannot support every candidate through Phase 3 trials, one alternative is to pool private capital, policy financing, and funds from large domestic pharmaceutical companies to invest over the long term in promising assets.


Of course, taking every drug candidate through Phase 3 trials in-house is not the only solution. For assets with a high likelihood of failure or requiring enormous sums for global clinical trials, it may be more reasonable to pursue joint development with global pharmaceutical companies or license them out at an early stage. Conversely, candidates with proven competitiveness can be advanced through Phase 2, with data collected directly to increase their value before a deal is signed. An industry official said, "Korean companies do not need to compete with China by producing dozens of drug candidates. Rather than hastily handing over even good assets because funding has run out, we need to create conditions that allow companies to decide for themselves which candidates to develop and which to discontinue."


Some say Korea also needs to further strengthen its clinical trial capabilities, an area where it has demonstrated strengths. China is rapidly improving the speed and quality of its clinical trials by leveraging large patient populations and clinical infrastructure, making it increasingly difficult for Korea to differentiate itself through fast and accurate trial execution alone.


A drug development researcher at a domestic university hospital said, "In the past, global pharmaceutical companies came to Korea because they had little confidence in the quality of clinical trials in China, but Chinese clinical data are now also recognized internationally. Korea needs to combine its strengths in translational research and biomarker discovery with drug development." The researcher added, "We need to create incentives and an environment that encourage domestic hospitals to actively participate not only in drug development for global Big Pharma companies, but also in the research and clinical trials of drug candidates from domestic biotech ventures."



Some also recommend finding areas for cooperation rather than engaging in an all-out race to catch up with China. As tensions between the United States and China increase uncertainty around Chinese biotech companies' entry into the U.S. market, Korea could connect its clinical infrastructure, medical professionals, and the research capabilities they have built up with Chinese companies to pursue cooperation and synergies in certain areas. This could also help Chinese companies expand globally. Lee said, "It is not realistic to try to catch up with China in every field. We should compete where necessary, but we also need a strategy for entering global markets alongside Chinese companies through clinical trials or joint development."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing